This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, R.-F. Search for Related Content PubMed PubMed Citation Articles by Wang, R.-F. Related Collections Therapeutics and Targets: Identification, Validation, and Markers Cancer Immunology Cancer Immunology: Immunotherapy

Regulatory T Cells and Toll-Like Receptors in Cancer Therapy

The 2^nd Hospital, Zhejiang University Medical School, Hangzhou, China and Center for Cell and Gene Therapy and Department of Immunology, Baylor College of Medicine, Houston, Texas

Requests for reprints: Rong-Fu Wang, Center for Cell and Gene Therapy and Department of Immunology, Baylor College of Medicine, ALKEK Building, N1120, Houston, TX 77030. Phone: 713-798-1244; Fax: 713-798-1263; E-mail: Rongfuw{at}bcm.tmc.edu.

T regulatory (Treg) cells that suppress immune responses may limit the efficiency of cancer immunotherapy. Recent findings indicate that Toll-like receptors (TLR) directly regulate the suppressive activity of Treg cells. Linking TLR signaling to the functional control of Treg cells may offer new opportunities to improve the outcome of cancer immunotherapy by coadminstration of certain TLR ligands. (Cancer Res 2006; 66(10): 4987-90)

This article has been cited by other articles:

				R. Casetti, C. Agrati, M. Wallace, A. Sacchi, F. Martini, A. Martino, A. Rinaldi, and M. Malkovsky Cutting Edge: TGF-{beta}1 and IL-15 Induce FOXP3+ {gamma}{delta} Regulatory T Cells in the Presence of Antigen Stimulation J. Immunol., September 15, 2009; 183(6): 3574 - 3577. [Abstract] [Full Text] [PDF]

				Regulatory T Cells and TLRs in Cancer Therapy Cancer Res., September 1, 2006; 66(17): 8925 - 8925. [Full Text] [PDF]